A Phase 1 Study of the Oral TRK Inhibitor LOXO-101 in Adult Patients with Solid Tumors
To establish a safe dose of the study drug (LOXO-101) by gathering information on how well it is tolerated, any potential side effects it may cause, and collecting data about how your cancer responds to the drug.
All solid tumors.
1. Female or male 18 years or older
2. Any solid tumor
3. Other criteria also apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
Until disease progression, unacceptable side effects, or participant's decision to withdraw from the study.
Knight Clinical Trials Information Line
Loxo Oncology Inc